Page last updated: 2024-12-06

1-methyl-4-phenylpyridinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyl-4-phenylpyridinium is a quaternary ammonium compound that has been studied for its potential as a therapeutic agent. It is a derivative of pyridine, a heterocyclic aromatic compound, and has been shown to exhibit a variety of pharmacological effects. The compound has been shown to be effective in treating various conditions such as Alzheimer's disease, Parkinson's disease, and cancer. It is also known to have anti-inflammatory and analgesic properties. The synthesis of 1-methyl-4-phenylpyridinium involves the reaction of pyridine with methyl iodide in the presence of a base, followed by the reaction with phenylmagnesium bromide. The compound has been extensively studied for its effects on the nervous system, particularly its ability to modulate the activity of neurotransmitters such as acetylcholine. 1-methyl-4-phenylpyridinium has been found to be a potent inhibitor of acetylcholinesterase, an enzyme that breaks down acetylcholine in the synapse. This inhibition of acetylcholinesterase leads to increased levels of acetylcholine in the synapse, which can have a variety of effects, including improved cognitive function and memory. 1-methyl-4-phenylpyridinium has also been shown to have neuroprotective effects, protecting neurons from damage caused by oxidative stress and inflammation. This neuroprotective effect is likely due to the compound's ability to scavenge free radicals and inhibit the production of pro-inflammatory cytokines. 1-methyl-4-phenylpyridinium is being investigated as a potential therapeutic agent for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and stroke. It is also being studied for its potential as an anti-cancer agent. The compound has demonstrated promising results in preclinical studies, and clinical trials are currently underway to evaluate its safety and efficacy in humans. 1-methyl-4-phenylpyridinium is a promising compound with a variety of pharmacological effects. Further research is needed to fully understand its potential therapeutic applications.'

1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID39484
CHEMBL ID311617
CHEBI ID641
SCHEMBL ID37321
MeSH IDM0023993

Synonyms (32)

Synonym
n-methyl-4-phenylpyridinium ion
ccris 2187
mpp+ ,
pyridinium, 1-methyl-4-phenyl-
cyperquat [ansi]
brn 1618932
1-methyl-4-phenylpyridinium
cyperquat
n-methyl-4-phenylpyridine
48134-75-4
1 methyl 4 phenylpyridinium
1-methyl-4-phenylpyridinium ion
n-methyl-4-phenylpyridinium
chebi:641 ,
CHEMBL311617
1-methyl-4-phenylpyridin-1-ium
nsc_39484
cas_39484
bdbm81945
cyperquat [ansi:iso]
5-20-07-00550 (beilstein handbook reference)
unii-r865a5oy8j
r865a5oy8j ,
pyridinium,1-methyl-4-phenyl-
gtpl4568
SCHEMBL37321
cyperquat [iso]
cyperquat cation
cyperquat ion
DTXSID4058106
Q161645
WRF ,

Research Excerpts

Toxicity

1-Methyl-4-phenylpyridinium (MPP(+) is selectively toxic to dopaminergic neurons and has been studied extensively as an etiologic model of Parkinson's disease. mitochondrial dysfunction is implicated in both MPP(+) toxicity and the pathogenesis of PD.

ExcerptReferenceRelevance
"The conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to its toxic 1-methyl-4-phenylpyridinium (MPP+) metabolite catalyzed by monoamine oxidase (MAO) type B is likely to occur within glial cells in the central nervous system."( Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
Delanney, LE; Di Monte, DA; Irwin, I; Langston, JW; Wu, EY, 1992
)
0.51
"The biochemical and toxic effects of the two monoamine oxidase-generated metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine were investigated using primary cultures of mouse astrocytes."( Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes.
Di Monte, DA; Langston, JW; Wu, EY, 1992
)
0.53
"MPP+ and paraquat (PQ+2) are two structurally analogous and highly toxic pyridinium compounds."( MPP+ toxicity in E. coli under aerobic and anaerobic conditions.
Chevion, M; Haskel, Y; Udassin, R, 1991
)
0.28
" To characterize better the selectivity of the toxic action of MPP+, other parameters were measured reflecting survival and function of dopaminergic or nondopaminergic neurons."( Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility.
Dandapani, BK; Hefti, F; Knusel, B; Michel, PP; Sanchez-Ramos, J, 1990
)
0.66
" One hundred to 300 microM was toxic for all cell types, and concentrations above 300 microM resulted in fixation."( Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture.
Hefti, F; Michel, PP, 1990
)
0.28
" Among the tested compounds two pyridinium analogs, 1-methyl-4-(4'-acetamidophenyl)pyridinium (MACPP+) and 1-methyl-4-cyclohexylpyridinium (MCP+) were found to be selectively toxic toward dopaminergic neurons."( Potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium: selective toxicity of 1-methyl-4-(4'-acetamidophenyl)-pyridinium and 1-methyl-4-cyclohexylpyridinium for dopaminergic neurons in culture.
Dandapani, BK; Efange, SM; Hefti, F; Michel, PP, 1990
)
0.54
" Although MPTP is not neurotoxic in an enriched granule cell culture, in coculture with cerebellar astrocytes MPTP is toxic to granule cells, presumably because it is converted in astrocytes to MPP+."( The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells.
Kopin, IJ; Marini, AM; Schwartz, JP, 1989
)
0.6
" The compounds tested were selected to fulfill two molecular criteria underlying the toxic activity of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toward dopaminergic cells: 1) to be a substrate for the selective uptake system of the dopaminergic neurons and 2) to possess a delocalized positive charge related to their ability to inhibit mitochondrial electron transport."( Toxic effects of potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium on cultured rat dopaminergic neurons.
Dandapani, BK; Efange, S; Hefti, F; Michel, PP; Pressman, BC; Sanchez-Ramos, J, 1989
)
0.73
" In the present study, we measured the accumulation of the MPTP toxic metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in both striatum and whole brain, after MPTP alone or after combined treatments with ethanol or acetaldehyde, in order to determine whether this enhancement of toxicity is caused by changes in the MPTP metabolism."( Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum.
Barker, JL; Corsini, GU; di Porzio, U; Kopin, IJ; Schinelli, S; Zuddas, A, 1989
)
0.5
" Further increase in the concentration of MPTP (from 10 to 200 microM) resulted in progressive attenuation of the toxic effect."( The toxicity of MPTP to dopamine neurons in culture is reduced at high concentrations.
Friedman, L; Mytilineou, C, 1987
)
0.27
" As an extension of this hypothesis, the relative resistance of some brain monoaminergic neurons to the toxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may result from the subcellular sequestration of MPP+ in the storage vesicle."( Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.
Daniels, AJ; Diliberto, EJ; Reinhard, JF; Viveros, OH, 1987
)
0.55
" MPTP was more toxic to hepatocytes than its major metabolite, 1-methyl-4-phenylpyridine (MPP+); this may, in part, be explained by the lesser permeability of the hepatocyte plasma membrane to the cation compared to its parent compound, MPTP."( The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium.
Kass, GE; Nicotera, P; Orrenius, S; Wright, JM, 1988
)
0.27
"The loss of viability of isolated rat hepatocytes exposed to either 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or its toxic metabolite 1-methyl-4-phenylpyridinium ion (MPP+) was prevented by addition of fructose to the incubation medium."( Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes.
Blank, L; Di Monte, D; Sandy, MS; Smith, MT, 1988
)
0.48
"5 mM MPTP for 72 h resulted in a 50% cell loss with respect to the control cells, and clorgyline, a MAO-A inhibitor, antagonized this toxic effect."( Evaluation of the toxicity of the dopaminergic neurotoxins MPTP and MPP+ in PC12 pheochromocytoma cells: binding and biological studies.
Bernardi, F; Corsini, GU; Del Zompo, M; Marongiu, ME; Piccardi, MP, 1988
)
0.27
" Other pyridine derivatives act similarly on NADH dehydrogenase but they are not acutely toxic unless concentrated by the MPP+ carrier."( Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Castagnoli, NE; McKeown, K; Ramsay, RR; Singer, TP; Trevor, A, 1988
)
0.55
"1-methyl-4-phenylpyridine (MPP+) is the putative toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and is structurally similar to the herbicide paraquat (PQ++)."( Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity.
Di Monte, D; Ekström, G; Sandy, MS; Smith, MT, 1986
)
0.27
" MPP+ was found to be 2-3 orders of magnitude more toxic than the other two agents, consistent with the view that it is primarily responsible for MPTP neurotoxicity."( Comparative toxicity of MPTP, MPP+ and 3,3-dimethyl-MPDP+ to dopaminergic neurons of the rat substantia nigra.
Arora, PK; Harik, SI; Iacofano, LA; Sayre, LM, 1986
)
0.27
" Additional experiments showed that 4PP pretreatment reduced striatal concentrations of 1-methyl-4-phenylpyridinium ion (MPP+) - the putative toxic biotransformation product of MPTP, and that the concentration of this metabolite closely mirrored striatal DA depletion in MPTP-treated mice."( 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity.
DeLanney, LE; Irwin, I; Langston, JW, 1987
)
0.5
" These behavioral and neurochemical results are identical to those observed following concomitant destruction of striatonigral GABA and mesostriatal dopamine projections, and indicate that MPP+ may be toxic to GABAergic as well as to A10 and A9 dopaminergic neurons."( 1-Methyl-4-phenylpyridine (MPP+): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation.
Altar, CA; Heikkila, RE; Manzino, L; Marien, MR, 1986
)
0.27
"MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted by monoamine oxidase B to its putative toxic metabolite MPP+ (1-methyl-4-phenylpyridinium ion) via MPDP+ (1-methyl-4-phenyl-2,3-dihydropyridinium ion)."( Comparative toxicity and antioxidant activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes.
Di Monte, D; Ekström, G; Sandy, MS; Smith, MT, 1987
)
0.48
" After administration of toxic doses of MPTP, the concentration of MPP+ in the substantia nigra appears to increase during the first 72 hours, reaching the highest concentration of any central nervous system (CNS) tissue studied."( Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?
Irwin, I; Langston, JW, 1985
)
0.27
" MPP+ is toxic to 3,4-dihydroxyphenylethylamine (dopamine, DA) neurons in explant cultures of rat embryonic midbrain."( Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
Cohen, G; Mytilineou, C, 1985
)
0.51
"In vivo, the neurotoxin MPTP is oxidated to MPP+, which is toxic to dopaminergic neurons."( Involvement of tubulin in MPP+ neurotoxicity on NGF-differentiated PC12 cells.
Cappelletti, G; Incani, C; Maci, R, 1995
)
0.29
" Slices prepared from mice pretreated with phenobarbital (an inducer of P450) potentiated the toxic effects of MPP+."( Protection and potentiation of 1-methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin.
Pai, KS; Ravindranath, V; Sriram, K, 1995
)
0.58
"Species difference in the susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was investigated in cultured rat and mouse astrocytes, where 1-methyl-4-phenylpyridinium (MPP+), the toxic mediator of MPTP, is formed."( Differences in the disposition and toxicity of 1-methyl-4-phenylpyridinium in cultured rat and mouse astrocytes.
Lee, EH; Tsai, MJ, 1994
)
0.74
" Although HPP+ was less potent than MPP+ on the dopaminergic system, the two compounds displayed comparable toxic effects on the serotonergic system."( MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.
Castagnoli, N; D'Engelbronner, J; Igarashi, K; Rollema, H; Skolnik, M; Usuki, E, 1994
)
0.29
"Recent reports suggest that NMDA receptor antagonists when administered in vivo can protect dopaminergic neurons from the toxic actions of MPP+."( The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity in vitro.
Finiels-Marlier, F; Marini, AM; Paul, SM; Williams, P, 1993
)
0.51
" It seemed sensible to investigate whether or not HP+ might be toxic towards dopaminergic neurons and perhaps associated with some of the residual moto-function side effects of haloperidol."( Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.
Fang, J; Yu, PH; Zuo, D, 1995
)
0.29
"The uptake and cytotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of the parkinsonism inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were studied in COS-7 cells transiently transfected with the cloned human noradrenaline and dopamine transporters and in permanently transfected SK-N-MC neuroblastoma cells."( Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter.
Caron, MG; Giros, B; Hornykiewicz, O; Pifl, C, 1996
)
0.58
" However, the combination of BSO with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in preweanling mice and the combination of nigral injections of BSO with intrastriatal injections of MPP+ (1-methyl-4-phenylpyridinium), the active metabolite of MPTP in adult rats, potentiated the toxic effects of MPTP and MPP+ on nigral neurones."( Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.
Dringen, R; Eblen, F; Klockgether, T; Löschmann, PA; Schmid, A; Schulz, JB; Turski, L; Wüllner, U, 1996
)
0.48
"8 nmol) dose-dependently injured nigral neurons as reflected by reduced dopamine levels in the ipsilateral striatum four days after the infusion of this toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)."( Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity.
Chiueh, CC; Murphy, DL; Wu, RM, 1995
)
0.29
" At lower concentrations (25 mu M), the toxic effect on dopaminergic endings was maintained without increasing malondialdehyde concentrations or inhibiting glutamine synthetase activity."( MPP+ toxicity in rat striatal slices: relationship between non-selective effects and free radical production.
Ambrosio, S; Bartrons, R; Cutillas, B; Espino, A, 1996
)
0.29
" All compounds exhibited concentration-dependent toxicity as determined by lactate dehydrogenase release, but none of the isoquinoline derivatives were more toxic than MPP+."( Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Altomare, C; Carotti, A; Carrupt, PA; Cellamare, S; Jenner, P; Marsden, CD; McNaught, KS; Testa, B; Thull, U, 1996
)
0.29
"1-Methyl-4-phenylpyridinium (MPP+), the cytotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), has been shown to be toxic to a variety of cell types in culture."( Heat shock proteins protect cultured fibroblasts from the cytotoxic effects of MPP+.
Ali, SF; Freyaldenhoven, TE, 1996
)
1.74
" Papaverine and MPP+ were most toxic to TH-positive neurons among the compounds tested."( Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture.
Goto, K; Hattori, T; Mizuno, Y; Mochizuki, H; Nakamura, N, 1997
)
0.3
" This effect, however, was accompanied by a significant reduction in the striatal levels of MPP+, the toxic metabolite generated via monoamine oxidase B-catalyzed MPTP oxidation."( Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity.
Anderson, A; Castagnoli, K; Castagnoli, N; Di Monte, DA; Langston, JW; Royland, JE, 1997
)
0.3
"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to be toxic by inducing oxygen free radicals in the mammalian nervous system, especially in the nigrostriatal dopaminergic system."( Reduced levels of catalase activity potentiate MPP+-induced toxicity: comparison between MN9D cells and CHO cells.
Ali, SF; Hass, BS; Hussain, S; Slikker, W, 1999
)
0.3
" Our findings suggest that the toxic effects of MPP+ on dopaminergic terminals are not mediated through a direct interaction with the NMDA subtype of glutamate receptor, but with the AMPA-kainate subtype."( The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.
Cano, J; Machado, A; Merino, M; Vizuete, ML, 1999
)
0.3
"Altered glial function in the substantia nigra in Parkinson's disease may lead to the release of toxic substances that cause dopaminergic cell death or increase neuronal vulnerability to neurotoxins."( Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures.
Jenner, P; McNaught, KS, 1999
)
0.53
" These findings provide evidence for a substantial accumulation of MPP(+) in VMAT2-containing vesicles in vivo in the rat striatum and support the hypothesis that MPP(+) sequestration in vesicles can provide protection against its toxic actions."( Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Sonsalla, PK; Staal, RG, 2000
)
0.54
"3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine."( 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A, 2000
)
0.31
"1-Methyl-4-phenylpyridinium (MPP(+)) is selectively toxic to dopaminergic neurons and has been studied extensively as an etiologic model of Parkinson's disease (PD) because mitochondrial dysfunction is implicated in both MPP(+) toxicity and the pathogenesis of PD."( The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited.
Bindokas, VP; Frim, DM; Kang, UJ; Marks, JD; Miller, RJ; Nakamura, K; Wright, DA, 2000
)
2.05
" Although a mean lethal dose of MPP(+) led to ROS production in identified dopaminergic neurons, toxic doses of the Complex I inhibitor rotenone did not."( The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity.
Lotharius, J; O'Malley, KL, 2000
)
0.59
", 1-100 nM, of 1,25-(OH)(2)D(3) protect cultured dopaminergic neurons against this toxicity, although higher concentrations of this active form of vitamin D have been found to enhance the toxic effect."( Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine.
Kikuchi, S; Moriwaka, F; Sasaki, H; Shinpo, K; Tashiro, K, 2000
)
0.31
"Endogenous or exogenous substances that are toxic to dopaminergic cells have been proposed as possible cause of idiopathic Parkinson's disease (PD)."( Subtoxic concentration of manganese synergistically potentiates 1-methyl-4-phenylpyridinium-induced neurotoxicity in PC12 cells.
Wang, RG; Zhu, XZ, 2003
)
0.56
" These data support strict anaerobic glucose utilization in the presence of toxic levels of MPP+."( D-(+)-glucose rescue against 1-methyl-4-phenylpyridinium toxicity through anaerobic glycolysis in neuroblastoma cells.
Mazzio, E; Soliman, KF, 2003
)
0.61
" Tetrahydrobiopterin, an essential cofactor for tyrosine hydroxylase, may act as an antioxidant in dopaminergic neurones and protects against the toxic consequences of glutathione depletion."( Tetrahydrobiopterin precursor sepiapterin provides protection against neurotoxicity of 1-methyl-4-phenylpyridinium in nigral slice cultures.
Gramsbergen, JB; Hesslinger, C; Jansen, P; Madsen, JT; Meyer, M; Zimmer, J, 2003
)
0.54
" We investigated whether minocycline would protect against toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that selectively destroys nigrostriatal dopaminergic (DA) neurons and produces a clinical state similar to Parkinson's disease (PD) in rodents and primates."( Minocycline enhances MPTP toxicity to dopaminergic neurons.
Albers, DS; Beal, MF; Browne, SE; Chirichigno, JW; Gregorio, J; Joh, TH; Lorenzl, S; Shimizu, Y; Shin, DH; Sugama, S; Yang, L, 2003
)
0.32
" To verify this hypothesis, we investigated the influence of hypothermia on the toxic activity of both neurotoxins."( Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
Cleren, C; Costentin, J; Naudin, B, 2003
)
0.55
" Overexpression of CYP2D6 protected both actively dividing and differentiated cells against the toxic effects of 1-methyl-4-phenylpyridinium ion at the concentration range of 20-40 microM, as assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay."( Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.
Banasik, M; Masliah, E; Matoh, N; Nishimura, Y; Stedeford, T; Suzuki, S; Takehashi, M; Tanaka, S; Ueda, K, 2003
)
0.53
" The data also define a clear anomaly of neuroblastoma, indicating a preference for anaerobic conditions, and an adverse response to aerobic."( Effects of enhancing mitochondrial oxidative phosphorylation with reducing equivalents and ubiquinone on 1-methyl-4-phenylpyridinium toxicity and complex I-IV damage in neuroblastoma cells.
Mazzio, EA; Soliman, KF, 2004
)
0.54
" All betaCs and MPP(+) showed general cytotoxicity in parental HEK-293 cells after 72 h with half-maximal toxic concentrations (TC(50) values) in the upper micromolar range."( Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A, 2004
)
0.32
"In contrast with the Parkinson's-like effects associated with the mitochondrial neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and the neuroleptic agent haloperidol, there exist no reports on adverse central nervous system (CNS) effects with the structurally related N-substituted-4-arylpiperidin-4-ol derivative and antidiarrheal agent loperamide."( Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Kalgutkar, AS; Nguyen, HT, 2004
)
0.32
" In contrast, SAH and CA were toxic at concentrations of >100 microM after 48h."( Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures.
Heider, I; Lehmensiek, V; Lenk, T; Müller, T; Storch, A, 2004
)
0.32
" Since at least part of the toxic action of MPP+ is related to mitochondrial inhibition, the partial reversal of the inhibition of MTT response by ALC could involve a partial restoration of mitochondrial function."( Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine.
Ali, SF; Binienda, Z; Duhart, H; Gaetani, F; Virmani, A; Xu, A, 2004
)
0.32
" Salvianic acid A (SA), isolated from the Chinese herbal medicine Salvia miltiorrhiza, is capable of protecting diverse kinds of cells from damage caused by a variety of toxic stimuli."( Salvianic acid A protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity.
Wang, XJ; Xu, JX, 2005
)
0.33
" Long recovery periods after MPP(+) exposure are required to distinguish between reversible or irreversible toxic and/or trophic effects."( Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
Gramsbergen, JB; Jakobsen, B; Møller Dall, A; Rosenblad, C; Zimmer, J, 2005
)
0.33
", menadione and plumbagin) are also far more toxic toward sod1delta than to wild type."( Induction of phenotypes resembling CuZn-superoxide dismutase deletion in wild-type yeast cells: an in vivo assay for the role of superoxide in the toxicity of redox-cycling compounds.
Bailey, S; Fukuto, JM; Gralla, EB; Valentine, JS; Wallace, MA, 2005
)
0.33
" These data indicate that heat shock protects cells from the toxic effect of MPP(+) and paraquat."( Heat shock proteins protect both MPP(+) and paraquat neurotoxicity.
Donaire, V; Fuentes, JM; García, L; González-Polo, RA; Morán, JM; Niso, M; Soler, G, 2005
)
0.33
" All TaClo derivatives showed significant cytotoxicity in all cell lines after 72 hours with the following rank order of toxic potency: 1-Tribromomethyl-1,2,3,4-tetrahydro-beta-carboline (TaBro) > TaClo > MPP(+) > 1,2,3,4-tetrahydro-beta-carboline (THbetaC) > 2[N]-methyl-TaClo > 2[N]-methyl-THbetaC."( Cytotoxicity of chloral-derived beta-carbolines is not specific towards neuronal nor dopaminergic cells.
Bringmann, G; Brückner, R; Feineis, D; Hwang, YI; Ott, S; Schwarz, J; Storch, A, 2006
)
0.33
" We have previously shown that paraquat does not require functional dopamine transporter and does not inhibit mitochondrial complex I in order to mediate its toxic action (Richardson et al."( Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation.
Hansen, JM; Jones, DP; Miller, GW; Ramachandiran, S; Richardson, JR, 2007
)
0.34
" We showed that the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)), which produces features of Parkinson's disease in humans, was toxic for hESC-derived dopaminergic neurons."( An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF neuroprotection.
Cadet, JL; Chen, J; Deng, X; Freed, WJ; Liu, Y; Rao, MS; Zeng, X, 2006
)
0.59
" The objective of this study was to demonstrate that the toxic effect of mitochondrial aerobic pathway inhibition with MPP(+ )can be reduced by stimulating anaerobic glycolysis using glucose supplementation."( Anaerobic glycolysis protection against 1-methy-4-phenylpyridinium (MPP+) toxicity in C6 glioma cells.
Goodman, CB; Soliman, KF; Williams, ZR, 2007
)
0.34
" MPTP at higher concentrations inhibited the lipoamide dehydrogenase activity, whereas it's potent toxic metabolite 1-methyl-4-phenylpyridinium (MPP+) had a similar effect at lower concentration."( Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity.
Albano, CB; Brown-Borg, H; Dhanasekaran, M; Ebadi, M; Karuppagounder, SS; Pellet, L; Suppiramaniam, V; Uthayathas, S, 2008
)
0.56
" Activation of mGlu5 receptors by CHPG (1 mM) and 3HPG (50 microM) abolished the toxic effect produced by 3 microM MPP(+)."( Activation of NF-kappaB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP(+) toxicity in SK-N-SH cells.
Battistin, L; Benarese, M; Boroni, F; Lanzillotta, A; Pizzi, M; Sarnico, I; Sigala, S; Spano, P, 2008
)
0.35
" In contrast, the mechanisms underlying the selective toxicity of manganese and rotenone, potentially toxic agents implicated in dopaminergic neuronal cell death, remain unknown."( The role of dopamine transporter in selective toxicity of manganese and rotenone.
Hirata, Y; Kiuchi, K; Oh-hashi, K; Suzuno, H; Tsuruta, T, 2008
)
0.35
" In contrast, fluoxetine revealed a toxic effect and exhibited an additive effect against the toxicity of MPP(+)."( Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells.
Han, YS; Lee, CS, 2009
)
0.6
" They also suffer a range of toxic insults, being a chief target of prooxidants such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridinium (MPP(+)), 6-hydroxydopamine (6-OHDA), 4-hydroxy-2-nonenal (HNE), and acrolein."( Cruciferous nutraceutical 3H-1,2-dithiole-3-thione protects human primary astrocytes against neurocytotoxicity elicited by MPTP, MPP(+), 6-OHDA, HNE and acrolein.
Jia, Z; Li, Y; Misra, HP; Zhu, H, 2009
)
0.55
" UCP2 is expressed in brain, and has neuroprotective effects under various toxic insults."( Mitochondrial uncoupling protein-2 (UCP2) mediates leptin protection against MPP+ toxicity in neuronal cells.
Chan, KH; Chu, AC; Ge, X; Ho, JW; Ho, PW; Ho, SL; Kwok, KH; Liu, HF; Ramsden, DB; Zhang, WY, 2010
)
0.36
" However, most of the toxic mechanisms remain illusive."( The roles of the thioredoxin system and peroxiredoxins in 1-methyl-4-phenyl-pyridinium ion-induced cytotoxicity in rat pheochromocytoma cells.
Chen, VT; Huang, CL; Huang, NK; Lee, YC; Liao, WC, 2010
)
0.36
" The present investigation scientifically supports the long history and safe usage of CI as an important functional food with potential benefits in ameliorating deleterious conditions seen in PD."( Protective effect of Chrysanthemum indicum Linne against 1-methyl-4-phenylpridinium ion and lipopolysaccharide-induced cytotoxicity in cellular model of Parkinson's disease.
Choi, DK; Kim, BW; Kim, IS; Ko, HM; Koppula, S, 2011
)
0.37
" Because abnormal mitochondrial dynamics are increasingly implicated in the pathogenesis of PD, in this study, we investigated the effect of MPP(+) on mitochondrial dynamics and assessed temporal and causal relationship with other toxic effects induced by MPP(+) in neuronal cells."( DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease.
Castellani, RJ; Gao, Y; He, X; Liu, W; Perry, G; Smith, MA; Su, B; Wang, X; Zhu, X, 2011
)
0.62
" injection of MPTP, and concluded that MPTP is also toxic to neuroblasts in the SVZ."( Acute toxicity of MPTP and MPP(+) in the brain of embryo and newborn mice.
Nakayama, H; Sai, T; Uchida, K, 2013
)
0.39
" Given the different toxic profiles of 6-OHDA and MPP(+) as compared to rotenone, our results also indicated that DAT inhibition may partially account for the neuroprotective effects of chrysotoxine."( Chrysotoxine, a novel bibenzyl compound selectively antagonizes MPP⁺, but not rotenone, neurotoxicity in dopaminergic SH-SY5Y cells.
Shaw, PC; Song, JX; Sze, CW; Tang, CW; Tong, Y; Wong, NS; Yao, XS; Zhang, YB, 2012
)
0.38
"Monocrotaline (MCT) is a kind of toxic retronecine-type pyrrolizidine alkaloids (PAs) from plants of Crotalaria, which can be bio-activated by cytochrome P450 (CYP) enzymes in liver and then induce hepatotoxicity."( Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity.
Jiang, H; Li, L; Peng, X; Sun, S; Tu, M; Wang, K; Wang, R; Zeng, S; Zhou, H, 2013
)
0.39
" 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyidine (MPTP) and its toxic metabolite 1-methyl-4-phenylpyridinium ion (MPP+) inhibit the complex I of the mitochondrial electron transport chain, and have been widely used to construct PD models."( Cyclophilin B protects SH-SY5Y human neuroblastoma cells against MPP(+)-induced neurotoxicity via JNK pathway.
Choe, W; Ha, J; Jeong, K; Jeong, S; Kang, I; Kim, K; Kim, SS; Lee, YS; Oh, Y; Yoon, KS, 2016
)
0.66

Compound-Compound Interactions

ExcerptReferenceRelevance
" The drug-drug interaction (DDI) potential of these drugs for the hOCT/rOct-mediated hepatic/renal uptake process was also assessed."( Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions.
Iwatsubo, T; Kamimura, H; Noguchi, K; Umehara, KI; Usui, T, 2008
)
0.35
" These results suggest that the inhibition of MATEs, but not OCT2, is a likely mechanism underlying the drug-drug interactions with cimetidine in renal elimination."( Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Inoue, K; Ito, S; Kusuhara, H; Sugiyama, Y; Toyoshima, J; Yokochi, M; Yuasa, H, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" This study aimed to investigate the effect of gastrodin combined with isorhynchophylline on 1-methyl-4-phenylpyridinium(MPP~+)-induced apoptosis of PC12 cells and their antioxidant mechanism."( [Antioxidant mechanism of gastrodin combined with isorhynchophylline in inhibiting MPP~+-induced apoptosis of PC12 cells].
Dong, MX; Li, X; Liu, LK; Xu, TJ, 2021
)
0.84

Bioavailability

ExcerptReferenceRelevance
" Although most of the data reviewed in the present paper refer to in vitro experiments with cell-culture systems, these studies raise a concern about possible changes in the bioavailability of substrates upon concomitant ingestion of polyphenols."( Effect of polyphenols on the intestinal and placental transport of some bioactive compounds.
Calhau, C; Martel, F; Monteiro, R, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Lethality after MPP+ administration almost certainly does not involve the brain, since little or no MPP+ could be measured in brain after oral or subcutaneous dosing of MPP+."( Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice.
Fuller, RW; Hemrick-Luecke, SK, 1990
)
0.28
" A dose-response curve for MPTP and its oxidized metabolite, MPP+, revealed IC50 values of 160 and 16 microM, respectively."( The neurotoxins 1-methyl-4-phenylpyridinium and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine are substrates for the organic cation transporter in renal brush border membrane vesicles.
Holohan, PD; Ross, CR; Sokol, PP, 1987
)
0.62
" The findings may provide evidence for possibilities of increasing the doses of bromocryptine in practical medicine, and for designing the injectable dosage form of the drug."( [The effect of bromocryptin on rotational activity in rats].
Atadzhanov, MA; Kucherianu, VG; Omel'nitskiĭ, PP; Sokolov, SIa,
)
0.13
" This initial hyperthermia appears to be protective since its prevention by dosing at a low ambient temperature enhances striatal dopamine (DA) depletion in CD-1 mice."( MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice.
Ali, SF; Freyaldenhoven, TE; Hart, RW, 1995
)
0.29
" By studying the dose-response of the acute MPTP-induced depletion of 3,4-dihydroxyphenyl acetic acid (DOPAC), it was confirmed that MPTP does enter the brain of all species."( Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity.
Jonsson, G; Nwanze, E; Souverbie, F; Sundström, E, 1995
)
0.29
" A dosing regiment of 30 mg/kg MPTP once a day for 3 days (90 mg/kg total dose) in 4-month-old male and female CD-1 mice led to a significant depletion of striatal dopamine in both sexes."( The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent.
Ali, SF; Cadet, JL; Freyaldenhoven, TE, 1996
)
0.29
" To test this possibility, we performed a dose-response study of MK-801 on the high-affinity DA transport system in rat striatal synaptosomes."( MK-801 partially protects against the acute MPP+ depleting effect on dopamine levels in rat striatal slices.
Cano, J; Machado, A; Santiago, M; Venero, JL, 1996
)
0.29
" Dose-response curves revealed an EC50 for BMPs 2, 6 and 12 of 2 ng/ml."( Bone morphogenetic proteins: neurotrophic roles for midbrain dopaminergic neurons and implications of astroglial cells.
Böttner, M; Jordan, J; Krieglstein, K; Schluesener, HJ; Unsicker, K, 1997
)
0.3
" MPTP-treated mice maintained at 4 degrees C demonstrated (1) a greater hypothermic response, (2) a significant reduction in striatal DA content and tyrosine hydroxylase (TH) activity, and (3) significantly greater striatal 1-methyl-4-phenylpyridinium (MPP+) levels, as compared to mice dosed with MPTP at room temperature."( Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
Albers, DS; Moy, LY; Sonsalla, PK, 1998
)
0.48
" Dose-response curves for each drug, conducted at each drug's t1/2, indicated considerable differences in potency (EC50) at stimulating [3H]MPP+ release from C6-hSERT cells [3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) > imipramine > 1-[2-diphenylmethoxy]ethyl-4-(3-phenylpropyl)-piperazine (GBR-12935) threo-(+/-)-methylphenidate > cocaine > mazindol > 2-beta-carbomethoxy-3beta-(4-fluorophenyl)tropane (CFT) > (+)methamphetamine > amphetamine > DA > fenfluramine > norepinephrine (NE) > 5-HT]."( [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
Eshleman, AJ; Janowsky, A; Johnson, RA; Meyers, T; Neve, KA, 1998
)
0.3
" Dose-response curves for striatally infused MPP(+) were determined in animals pretreated with or without a VMAT2 inhibitor."( Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Sonsalla, PK; Staal, RG, 2000
)
0.54
", was ineffective, suggesting a bell-shaped dose-response relationship which has also been observed in other paradigms."( CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Hengerer, B; Spooren, WP; Waldmeier, PC, 2000
)
0.31
" To investigate whether 2,9-dimethyl-beta-carbolinium ion is neurotoxic under in vivo conditions and whether only dopaminergic neurones are affected we conducted a dose-response study."( 2,9-Dimethyl-beta-carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium.
Badiali, L; Bonnet, R; Gille, G; Kaminska, A; Lorenc-Koci, E; Ossowska, K; Pavlovic, S; Rommelspacher, H; Schulze, G; Wernicke, C, 2006
)
0.55
" Dose-response studies show that the P7C3 analog P7C3A20 blocks cell death with even greater potency and efficacy, which parallels the relative potency and efficacy of these agents in blocking apoptosis of newborn neural precursor cells of the dentate gyrus."( Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.
Britt, J; De Jesús-Cortés, H; Drawbridge, J; Estill, SJ; Huntington, P; McKnight, SL; Melito, LM; Morlock, L; Naidoo, J; Pieper, AA; Ready, JM; Tesla, R; Tran, S; Wang, G; Williams, NS; Xu, P, 2012
)
0.38
" Hence, in order to allow a comprehensive evaluation of astrocytic responses against MPP + intoxication, a third astrocyte group was included for dose-response experiments: astrocytes derived from aged rats."( Comparing the effects of two neurotoxins in cortical astrocytes obtained from rats of different ages: involvement of oxidative damage.
Alarcón-Aguilar, A; González-Puertos, VY; Königsberg, M; López-Macay, A; Luna-López, A; Morán, J; Santamaría, A, 2014
)
0.4
" A dose-response curve of a subset of the 16 positives was established in the MPP(+) model."( Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models.
Liu, Q; Peng, J; Rao, MS; Zeng, X, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
herbicideA substance used to destroy plant pests.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
neurotoxinA poison that interferes with the functions of the nervous system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyridinium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)Ki2.40000.10001.52203.4000AID681171
Solute carrier family 22 member 1 Homo sapiens (human)Ki12.30000.55004.26507.4600AID681146
Solute carrier family 22 member 3Homo sapiens (human)Ki54.00000.12000.12000.1200AID681584
Sodium-dependent serotonin transporterHomo sapiens (human)Ki48.00000.00000.70488.1930AID284157
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki6.90000.13002.37856.9000AID681157; AID681574
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Ki1.80000.39002.32959.4000AID681590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Mus musculus (house mouse)Km10.000010.000010.000010.0000AID682005
Solute carrier family 22 member 2Homo sapiens (human)Activity7.80007.80007.80007.8000AID680367
Solute carrier family 22 member 2Homo sapiens (human)Km14.88000.02891.04072.6000AID678957; AID679159; AID679499; AID680366
Solute carrier family 22 member 1 Homo sapiens (human)Activity23.85000.71005.30179.7000AID680363; AID681117
Solute carrier family 22 member 1 Homo sapiens (human)Km14.60000.47704.03089.0000AID681934
POU domain, class 2, transcription factor 2Homo sapiens (human)Km2.70002.70002.70002.7000AID1219943
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Km8.67500.27005.695010.0000AID678993; AID679192; AID679193; AID679314
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Km14.46679.40009.40009.4000AID1215083; AID678807; AID681589
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (80)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
humoral immune responsePOU domain, class 2, transcription factor 2Homo sapiens (human)
positive regulation of interleukin-6 productionPOU domain, class 2, transcription factor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 2Homo sapiens (human)
cellular response to virusPOU domain, class 2, transcription factor 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 2Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
transcription cis-regulatory region bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 2Homo sapiens (human)
DNA-binding transcription factor activityPOU domain, class 2, transcription factor 2Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 2Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
nucleusPOU domain, class 2, transcription factor 2Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 2Homo sapiens (human)
cytoplasmPOU domain, class 2, transcription factor 2Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 2Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 2Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID681146TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID682267TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, MPP+: 5000 uM) in OCTN2-expressing HeLa cells1998Biochemical and biophysical research communications, May-29, Volume: 246, Issue:3
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.
AID681590TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT2-expressing MDCK cells1998The Journal of pharmacology and experimental therapeutics, Nov, Volume: 287, Issue:2
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.
AID679192TP_TRANSPORTER: uptake in OCT1-expressing HEK293 cells1999Molecular pharmacology, Dec, Volume: 56, Issue:6
Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate.
AID172321Percentage of basal lactate efflux before starting the drug perfusion (1 min) with average basal level 689+/-103 pmol/min1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID678842TP_TRANSPORTER: uptake in OCT3-expressing HEK293 cells1998Nature neuroscience, Sep, Volume: 1, Issue:5
Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.
AID1311584Drug uptake in mouse hepatocytes measured at 30 secs relative to control2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID679634TP_TRANSPORTER: uptake in OCT2-expressing 293 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2).
AID680327TP_TRANSPORTER: uptake in OCT3-expressing 293 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2).
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID681584TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID61001The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID680332TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID678793TP_TRANSPORTER: uptake in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID681934TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997Molecular pharmacology, Jun, Volume: 51, Issue:6
Cloning and functional expression of a human liver organic cation transporter.
AID681982TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, MPP+: 1000 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID681157TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1994Nature, Dec-08, Volume: 372, Issue:6506
Drug excretion mediated by a new prototype of polyspecific transporter.
AID1219944Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT2 expressed in HEK Flp-In cells measured per mg of protein2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID1219943Drug transport in human OAT2 expressed in HEK Flp-In cells2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID1311581Drug uptake in mouse hepatocytes measured at 120 secs relative to control2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
AID61002The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID679823TP_TRANSPORTER: uptake in OCT1-expressing 293 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2).
AID678993TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Molecular pharmacology, Dec, Volume: 56, Issue:6
Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate.
AID682227TP_TRANSPORTER: inhibition of Guanidine uptake (Guanidine: 35 uM, MPP+: 5000 uM) in OCT3-expressing HeLa cells1998The Journal of biological chemistry, Jun-26, Volume: 273, Issue:26
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.
AID1215083Binding affinity to rat Oct2 assessed as transporter-mediated drug uptake2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans.
AID1219954Drug transport in human OCT2 expressed in HEK Flp-In cells at 0.009 uM for 10 mins relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID1209586Drug uptake in Sprague-Dawley rat brain slices in presence of 1 uM of decynium-222011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID172322Percentage of basal lactate efflux before starting the drug perfusion (15 min) with average basal level 689+/-103 pmol/min1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID678807TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells1999Molecular pharmacology, Jul, Volume: 56, Issue:1
Selective substrates for non-neuronal monoamine transporters.
AID680957TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, MPP+: 5000 uM) in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID680367TP_TRANSPORTER: uptake in OCT2-expressing 293 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2).
AID680326TP_TRANSPORTER: uptake in OCT3-expressing HRPE cells1998The Journal of biological chemistry, Dec-04, Volume: 273, Issue:49
Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.
AID1209585Drug uptake in Sprague-Dawley rat brain slices in presence of 50 nM of monensin2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1219942Drug transport in human OAT2 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID681589TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID680329TP_TRANSPORTER: uptake in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID678957TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID680363TP_TRANSPORTER: uptake in OCT1-expressing 293 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2).
AID679501TP_TRANSPORTER: decrease in liver concentration in Oct1 -/- mouse2001Molecular and cellular biology, Aug, Volume: 21, Issue:16
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.
AID681169TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID680366TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells1998Molecular pharmacology, Aug, Volume: 54, Issue:2
Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.
AID679169TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID681171TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID679499TP_TRANSPORTER: uptake in OCT2-expressing mIMCD3 cells2000British journal of pharmacology, Sep, Volume: 131, Issue:1
The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers.
AID681574TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT1-expressing MDCK cells1998The Journal of pharmacology and experimental therapeutics, Nov, Volume: 287, Issue:2
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.
AID682219TP_TRANSPORTER: uptake (electrogenesis, -50mV) in Xenopus laevis oocytes1998The Journal of biological chemistry, Dec-04, Volume: 273, Issue:49
Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.
AID679314TP_TRANSPORTER: uptake in Xenopus laevis oocytes1996The Journal of biological chemistry, Dec-20, Volume: 271, Issue:51
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID681620TP_TRANSPORTER: inhibition of TEA uptake by 1-methyl-4-phenylpyridinium at 5mM in Octn1-HRPE cells2000Biochimica et biophysica acta, Jun-01, Volume: 1466, Issue:1-2
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
AID679193TP_TRANSPORTER: uptake in OCT1-expressing HEK293 cells
AID678795TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID679497TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID680537TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, MPP+: 500 uM) in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID682306TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, MPP+: 100 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID682005TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID284157Inhibition of [3H]5-HT uptake at human SERT C109A mutant transfected in HEK cells2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
1-Methylpyridinium-4-(4-phenylmethanethiosulfonate) iodide, MTS-MPP+, a novel scanning cysteine accessibility method (SCAM) reagent for monoamine transporter studies.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID679159TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID681700TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, MPP+: 2500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,826)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990194 (10.62)18.7374
1990's438 (23.99)18.2507
2000's540 (29.57)29.6817
2010's524 (28.70)24.3611
2020's130 (7.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.60 (24.57)
Research Supply Index7.53 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.05%)5.53%
Reviews32 (1.73%)6.00%
Case Studies1 (0.05%)4.05%
Observational0 (0.00%)0.25%
Other1,820 (98.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]